MarketCapExport financials
HTG Molecular Diagnostics (HTGM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
HTG Molecular Diagnostics Cash Flow 2022-2011 | HTGM
Brief overview of HTG Molecular Diagnostics's cash generation
The review uses the five latest available annual reports between 2018 and 2022.
Cash from operations is below zero at -$18.4 million, increasing dependence on cash reserves or outside financing.
Core operations generated cash in 0 of five years. Frequent negative periods raise financial risk.
Working capital declined $3.3 million, or 51.8% of sales, temporarily strengthening cash generation.
Conclusion
HTG Molecular Diagnostics's cash flows remain vulnerable. Negative or unstable generation materially reduces financial flexibility.
Annual Cash Flow HTG Molecular Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-18.4 M | -16.5 M | -16.3 M | -16.7 M | -13.2 M | -16.6 M | - | - | - | - | - | - |
Depreciation & Amortization |
587 K | 721 K | 1.35 M | 1.26 M | 1.47 M | 1.24 M | 1.47 M | 663 K | 497 K | - | - | - |
Accounts Payables |
1.16 M | 1.65 M | 1.35 M | 1.66 M | 1.85 M | 2.44 M | 762 K | 725 K | 948 K | - | - | - |
Accounts Receivables |
1.42 M | 2.09 M | 1.59 M | 3.16 M | 5.01 M | 6.36 M | 1.38 M | 716 K | 801 K | - | - | - |
Total Inventories |
909 K | 1.99 M | 1.49 M | 1.27 M | 1.31 M | 1.18 M | 1.51 M | 2.2 M | 1.69 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow HTG Molecular Diagnostics
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-4.36 M | - | -16.4 M | -11.8 M | -5.94 M | - | -13.1 M | -8.9 M | -4.35 M | - | -12.7 M | -8.38 M | -3.93 M | - | -12.8 M | -8.77 M | -5.59 M | - | -10.6 M | -7.01 M | -2.7 M | - | -13.7 M | -9.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
86.1 K | - | 100 K | 200 K | 185 K | - | 200 K | 200 K | 198 K | - | 300 K | 400 K | 349 K | - | 317 K | 294 K | 309 K | - | 348 K | 422 K | 356 K | - | 306 K | 291 K | 296 K | - | 358 K | 372 K | 357 K | - | 474 K | 299 K | 151 K | - | 365 K | 241 K | 120 K | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
1.1 M | - | 710 K | 1.12 M | 1.32 M | 1.65 M | 1.15 M | 1.68 M | 1.35 M | 1.35 M | 875 K | 928 K | 1.67 M | 1.66 M | 3.02 M | 3.36 M | 1.41 M | 1.85 M | 1.87 M | 1.31 M | 2.22 M | 2.44 M | 2.69 M | 1.34 M | 1.19 M | 762 K | 1.12 M | 1.61 M | 2.23 M | 725 K | 967 K | 1.19 M | 879 K | 948 K | 948 K | 948 K | 948 K | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
1.13 M | - | 960 K | 1.26 M | 749 K | 2.09 M | 1.9 M | 1.42 M | 1.25 M | 1.59 M | 1.37 M | 1.01 M | 1.2 M | 3.16 M | 3.93 M | 3.98 M | 3.35 M | 5.01 M | 3.36 M | 3.48 M | 2.84 M | 6.36 M | 3.16 M | 1.55 M | 1.2 M | 1.38 M | 592 K | 1.91 M | 575 K | 716 K | 697 K | 554 K | 852 K | 801 K | 801 K | 801 K | 801 K | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
655 K | - | 1.69 M | 1.96 M | 2.02 M | 1.99 M | 2.34 M | 2.32 M | 1.6 M | 1.49 M | 1.54 M | 1.39 M | 1.64 M | 1.27 M | 1.19 M | 1.16 M | 1.18 M | 1.31 M | 1.13 M | 1 M | 1.04 M | 1.18 M | 1.25 M | 1.31 M | 1.26 M | 1.51 M | 1.87 M | 2.21 M | 2.37 M | 2.2 M | 2.27 M | 2.41 M | 2.1 M | 1.69 M | 1.69 M | 1.69 M | 1.69 M | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company HTG Molecular Diagnostics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Neuronetics
STIM
|
$ 2.01 | -7.8 % | $ 133 M |  USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
$ 155.43 | -2.12 % | $ 19.5 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
$ 10.63 | -8.68 % | $ 361 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
$ 311.81 | -1.92 % | $ 42.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 275.46 | -1.21 % | $ 47.4 B | USA |
 |
Agilent Technologies
A
|
$ 178.84 | -0.74 % | $ 50.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M |  Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
$ 79.92 | -1.42 % | $ 31.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 258.38 | -0.5 % | $ 28.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 34.41 | 0.07 % | $ 997 M | USA |
 |
IDEXX Laboratories
IDXX
|
$ 696.77 | -1.4 % | $ 56 B | USA |
 |
Illumina
ILMN
|
$ 214.84 | -2.69 % | $ 33.3 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.05 | -3.48 % | $ 99 K | USA |
|
Biodesix
BDSX
|
$ 10.04 | -2.95 % | $ 75.8 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.25 | 7.66 % | $ 6.81 M | USA |
 |
Bioventus
BVS
|
$ 11.18 | 1.5 % | $ 745 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 25.83 | -1.22 % | $ 795 M | USA |
 |
CareDx, Inc
CDNA
|
$ 80.78 | -4.31 % | $ 4.3 B | USA |
 |
Biomerica
BMRA
|
$ 1.48 | -4.52 % | $ 4.31 M | USA |
 |
Interpace Biosciences
IDXG
|
$ 7.0 | -13.43 % | $ 31 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 204.62 | -1.43 % | $ 16 B |  Irlanda |
 |
Co-Diagnostics
CODX
|
$ 0.29 | -9.5 % | $ 386 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 13.19 | 6.46 % | $ 135 M |  China |
 |
DarioHealth Corp.
DRIO
|
$ 2.37 | 15.05 % | $ 9.44 M | Israel |
 |
Myriad Genetics
MYGN
|
$ 5.66 | -1.39 % | $ 524 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 4.78 | -1.24 % | $ 3.76 M | USA |
 |
QIAGEN N.V.
QGEN
|
$ 50.52 | -0.07 % | $ 11 B |  Niderland |
 |
NeoGenomics
NEO
|
$ 16.97 | -3.58 % | $ 2.17 B | USA |
 |
OPKO Health
OPK
|
$ 1.71 | 0.58 % | $ 1.28 B | USA |
 |
Pacific Biosciences of California
PACB
|
$ 2.22 | -5.93 % | $ 666 M | USA |
 |
Neogen Corporation
NEOG
|
$ 11.67 | -3.44 % | $ 2.54 B | USA |